

**Europass
Curriculum Vitae**



Personal information

First name(s) / Surname(s) Braicu Cornelia
 Address(es) Fabricii de Zahar, nr 11 Cluj-Napoca, Romania
 Telephone(s) - Mobile: +40 (754)303833
 E-mail braicucornelia@yahoo.com
 Nationality Romanian
 Date of birth 08.04.1979
 Gender Female

Work experience

Dates **2017-present**
 Occupation or position held **Associate professor**
 Main activities and responsibilities ► Functional genomics studies (miRNA and mRNA) ► Molecular characterization - targeted therapies ► RNA interference ► Research studies/assimilation/optimization/validation of genetic and genomic methods applied in molecular diagnosis ► Responsible for quality assurance in the laboratory ► Expert advice on functional genomics ► Trainings training for PhD students, post-doctoral students in life sciences area.
 Name and address of employer Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy

Dates **2013-2017**
 Occupation or position held **Researcher**
 Main activities and responsibilities Cellular and molecular biology studies: analysis and gene expression level of expression and proteins involved in apoptosis, angiogenesis, RNA interference
 Name and address of employer Researcher at Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy

Dates **2008-2013**
 Occupation or position held **PostDoc**

Main activities and responsibilities	Cellular and molecular biology studies: genes and proteins analysis involved in apoptosis, angiogenesis. RNA interference.
Name and address of employer	Prof. Dr. I Chircuta Oncology Institute Cluj-Napoca, 34-36 Republicii str, 400015, Cluj-Napoca, Romania
Dates	01.08.2007-30.05.2008
Occupation or position held	Research Fellowship
Main activities and responsibilities	Immunomycotoxicology: MAPK (mitogen activated proteine kinases) and NF κ B (nuclear factor κ B) pathways, tight junctions proteins expression (western blot and immunofluorescence)
Name and address of employer	INRA, UR66, Laboratory of Pharmacology-Toxicology, <i>Toulouse, France</i>
Dates	01.10.2004-30.09.2008
Occupation or position held	PhD student Biotechnology area
Main activities and responsibilities	Cell cultures. Proteomics. <i>In vitro</i> toxicology tests
Name and address of employer	University of Agricultural Sciences and Veterinary Medicine, str Manastur, nr.3 Cluj-Napoca, Romania
Education and training	
Dates	01.09.2005-01.02. 2006
Title of qualification awarded	Master Degree, Biotechnology Applied in the Food Industry
Principal subjects/occupational skills covered	Biotechnology, General biology, genetics, chemistry
Name and type of organisation providing education and training	University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca
Dates	01.10.1999-01.06.2004
Title of qualification awarded	Biochemical Engineering
Principal subjects/occupational skills covered	Chemistry, Biochemistry, Chemical Engineering, Bioprocesses

Name and type of organisation providing education and training | University Babeş-Bolyai Cluj-Napoca, Faculty of Chemistry and Chemical

Personal skills and competences

Mother tongue(s) | Romanian

Other languages
Self
assessment
European level ()*

Understanding				Speaking				Writing	
Listening		Reading		Spoken interaction		Listening		Reading	
B2	Basic user	B2	Basic user	B2	Basic user	B2	Basic user	B2	Basic User

English

(*) [Common European Framework of Reference for Languages](#)

French

Organisational skills and competences | Team work, Self- confidence and ability of quick- learning, Oriented towards continuous professional development, Sociable, communicative, Easy- adaptable

Technical skills and competences | Cell cultures, ELISA, Western Blot
Microarray, PCR array, Real Time PCR.

Computer skills and competences | WINDOWS applications, Word, Excel, Power Point, specialized software

Publication:

- **One book, five international book chapters, two national book chapters**
- **Two breved proposal**
- **Over 75 ISI papers, with a total impact number of over 300 impact factor points** (Pubmed link: <https://www.ncbi.nlm.nih.gov/pubmed/?term=braicu+c>)
- **H-index: 20**
- **Total number of citations: 810** (excluding self citation)

Relevant 10 publication:

1. **Braicu C**, Buduru S, Zimta A-A, G D, Olariu A, Berindan-Neagoe I., Comprehensive analysis of circular RNAs in pathological states: biogenesis, cellular regulation and therapeutic relevance. *Cell Mol Life Sci*, DOI: 10.1007/s00018-019-03016-5 **IF: 6.72, Citation: 0**
2. **Braicu C**, Gulei D, Cojocneanu R, Lajos R, Jurj A, Knutsen E, Calin GA, Berindan-Neagoe I. MiRNAs-181a/b therapy in lung cancer: reality or myth?. *Mol Oncol*. 2018 Dec 8. doi: 10.1002/1878-0261.12420. **IF:5.264; Citation: 1**
3. **Braicu C**, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, Berindan-Neagoe I. Aberrant miRNAs expressed in HER-2 negative breast cancers patient. *J Exp Clin Cancer Res*. 2018 Oct 20;37(1):257. **IF: 6.217, Citation: 0**

4. Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, Berindan-Neagoe I. Nutrigenomics in cancer: Revisiting the effects of natural compounds. *Semin Cancer Biol.* 2017 Oct;46:84-106. **IF: 10.198, Citation: 11**
5. Gulei D, Mehterov N, Ling H, Stanta G, Braicu C, Berindan-Neagoe I. The "good-cop bad-cop" TGF-beta role in breast cancer modulated by non-coding RNAs. *Biochim Biophys Acta Gen Subj.* 2017 Jul;1861(7):1661-1675. **IF: 4.81 , Citation: 13**
6. Braicu C, Chiorean R, Irimie A, Chira S, Tomuleasa C, Neagoe E, Paradiso A, Achimas-Cadariu P, Lazar V, Berindan-Neagoe I. Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. *Expert Rev Mol Med.* 2016 Nov 7;18:e18. **IF: 5.149, Citation: 13**
7. Braicu C, Cojocneanu-Petric R, Jurj A, Gulei D, Taranu I, Gras AM, Marin DE, Berindan-Neagoe I. Microarray based gene expression analysis of Sus Scrofa duodenum exposed to zearalenone: significance to human health. *BMC Genomics.* 2016 Aug 17;17:646. **IF: 4.257, Citation: 5**
8. Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I. Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model. *PLoS One.* 2015 Apr 7;10(4):e0120936. **IF: 3.352, Citation: 10**
9. Braicu C, Tomuleasa C, Monroig P, Cucuianu A, Berindan-Neagoe I, Calin GA. Exosomes as divine messengers: are they the Hermes of modern molecular oncology?. *Cell Death Differ.* 2015 Jan; 22(1) :34-45. doi: 10.1038/cdd.2014.130. **IF: 8.218, Citation: 115**
10. Braicu C, Gherman CD, Irimie A, Berindan-Neagoe I. Epigallocatechin-3-Gallate (EGCG) Inhibits Cell Proliferation and Migratory Behaviour of Triple Negative Breast Cancer Cells. *J Nanosci Nanotechnol.* 2013 Jan;13(1):632-7. **IF: 1.34, Citation: 38**

Books: Irimie AI, Bran S, Berindan-Neagoe I, Braicu C, Gulei D., *Molecular Perspectives in Oral Cancer: an updated view*, Editura Eikon& Scoala Ardeleana, ISBN Eikon:978-606-711-848-3, ISBN Scoala Ardeleana: 978-606-797-282-5, Bucuresti, 2018 (134 pages)

Co-author for one immunology course, 2 book chapters on Monograph (Mircea Grigorescu, Alexandru Irimie Mirecea Beuran, *Tratat de oncologie digestiva*, Volume III)

International book chapters:

- ▶ 1. *Genomic Applications in Pathology*, Publisher: Springer, edition 09/2014; ISBN: 978-1493907267 Editors: George Netto, Iris Schrijver, New York, USA, 2014- Chapter: **MiRNA Expression Assays**, Braicu C, Maia B, Berindan-Neagoe I, Călin G, pages 45-70;
- ▶ 2. **Cancer Research and Clinical Trials in Developing Countries A practical Guide**, Springer International Publishing (Verlag), ISBN 978-3-319-18442-5; DOI 10.1007/978-3-319-18443-2, Editor Daniela Cristina Stefan, MD, PhD, USA, 2016- Chapter: **Types of Research Design**, Moissenko F, Braicu C, Tomuleasa C, and Berindan-Neagoe I, pages 29-41;
- ▶ 3. **Physiologic and Pathologic Angiogenesis - Signaling Mechanisms and Targeted Therapy** book edited by Dan Simionescu and Agneta Simionescu, Intechopen ISBN 978-953-51-3024-6, Print ISBN 978-953-51-3023-9, <http://dx.doi.org/10.5772/66529>, 2017- Chapter 14: **Noncoding RNAs in Lung Cancer Angiogenesis**, *Noncoding RNAs in Lung Cancer Angiogenesis*, Berindan-Neagoe I, Braicu C, Gulei D, Tomuleasa C, Calin GA; pages 29-41- *considered a highly accessed book chapter*
- ▶ 4. *Handbook of Foodborne Diseases*, 1st ed, Taylor Taylor and Francis CRC Press Boca Raton, a volume entitled under the Food Microbiology series, eBook ISBN9781351863490, 2018, Edited By Dongyou Liu, Chapter 92: **New mechanisms insights in human health of Zearalenone**, Braicu C, Zimta AA, Berindan-Neagoe I, pages 12
- ▶ 5. *Genomic Applications in Pathology*, Publisher: Springer, edition II Editors: George Netto, Iris Schrijver, Editors: George Netto, Iris Schrijver, New York, USA, Chapter: **MiRNA expression assays, past, present and future**, Braicu C, Maia B, Gulei D, Berindan-Neagoe I, Călin G, 2019, 45-70

Granted patents:

- ▶ Multitargeted method of inducing apoptosis in triple negative breast tumor cells; Braicu C, Pileczki V, Neagoe I, Irimie A, OSIM No. A/00082/ 31.01.2014.
- ▶ Non-invasive molecular diagnostic test for bladder cancer, Floares Al, Fersigan M, Braicu C, Petric R-M, Berindan-Neagoe I, Brevet Nr. A/00984/08.12.2016.

Prizes/Awards

- ▶ Romanian national prize of the **program L'Oréal- UNESCO FOR WOMEN IN SCIENCE**, section Life Sciences Section- 4th edition (2012 - 2013)
- ▶ **Excellence Award and the Gold Medal**, for the brevet "*Noninvasive molecular diagnostic test for bladder cancer*" at International Salon of Scientific Research, Innovation and Invention, "PRO INVENT" Cluj-Napoca, 2017, 15th edition
- ▶ **Excellence Award and the Gold Medal, for the brevet "*Noninvasive molecular diagnostic test for bladder cancer*"** at Forum of Romanian Inventors EuroInvent 2017, Iași
- ▶ **Excellence Award and the Gold Medal** for the brevet "*Multitargeted method of inducing apoptosis in triple negative breast cancer cells*" International Salon of Scientific Research, Innovation and Invention, "PRO INVENT" Cluj-Napoca, 2016, 12th edition

I hereby state on my own responsibility that the data presented is accurate.

Date: 14.03.2018